Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy

R. Taylor Ripley, Jeremy L. Davis, Jacob A. Klapper, Aarti Mathur, Udai Kammula, Richard E. Royal, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Steven K. Libutti, Donald E. White, Seth M. Steinberg, Mark E. Dudley, Steven A. Rosenberg, Itzhak Avital

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. Methods: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. Results: A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. Conclusions: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalAnnals of Surgical Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Melanoma
Survival
Liver
Therapeutics
Genetic Therapy
Disease-Free Survival
Multivariate Analysis
Databases
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Ripley, R. T., Davis, J. L., Klapper, J. A., Mathur, A., Kammula, U., Royal, R. E., ... Avital, I. (2010). Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Annals of Surgical Oncology, 17(1), 163-170. https://doi.org/10.1245/s10434-009-0677-0

Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. / Ripley, R. Taylor; Davis, Jeremy L.; Klapper, Jacob A.; Mathur, Aarti; Kammula, Udai; Royal, Richard E.; Yang, James C.; Sherry, Richard M.; Hughes, Marybeth S.; Libutti, Steven K.; White, Donald E.; Steinberg, Seth M.; Dudley, Mark E.; Rosenberg, Steven A.; Avital, Itzhak.

In: Annals of Surgical Oncology, Vol. 17, No. 1, 01.2010, p. 163-170.

Research output: Contribution to journalArticle

Ripley, RT, Davis, JL, Klapper, JA, Mathur, A, Kammula, U, Royal, RE, Yang, JC, Sherry, RM, Hughes, MS, Libutti, SK, White, DE, Steinberg, SM, Dudley, ME, Rosenberg, SA & Avital, I 2010, 'Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy', Annals of Surgical Oncology, vol. 17, no. 1, pp. 163-170. https://doi.org/10.1245/s10434-009-0677-0
Ripley, R. Taylor ; Davis, Jeremy L. ; Klapper, Jacob A. ; Mathur, Aarti ; Kammula, Udai ; Royal, Richard E. ; Yang, James C. ; Sherry, Richard M. ; Hughes, Marybeth S. ; Libutti, Steven K. ; White, Donald E. ; Steinberg, Seth M. ; Dudley, Mark E. ; Rosenberg, Steven A. ; Avital, Itzhak. / Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 1. pp. 163-170.
@article{877dedb34b69453c9826509689239f3b,
title = "Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy",
abstract = "Background: Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. Methods: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. Results: A total of 539 patients had MML, and 39{\%} (204 of 539) had tumor collected for TIL. A total of 17{\%} (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53{\%}. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31{\%} (11 of 35) underwent complete resection without TIL, and 69{\%} (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80{\%}. A total of 4 (44{\%}) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69{\%}) with residual disease, 3-year survival was 51{\%} (2 of 24 excluded for gene therapy). A total of 63{\%} (15 of 24) received postoperative TIL (3-year survival 65{\%}), and 29{\%} (7 of 24) did not. A total of 40{\%} (6 of 15) had disease that partially responded to TIL; the disease of 67{\%} (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. Conclusions: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.",
author = "Ripley, {R. Taylor} and Davis, {Jeremy L.} and Klapper, {Jacob A.} and Aarti Mathur and Udai Kammula and Royal, {Richard E.} and Yang, {James C.} and Sherry, {Richard M.} and Hughes, {Marybeth S.} and Libutti, {Steven K.} and White, {Donald E.} and Steinberg, {Seth M.} and Dudley, {Mark E.} and Rosenberg, {Steven A.} and Itzhak Avital",
year = "2010",
month = "1",
doi = "10.1245/s10434-009-0677-0",
language = "English (US)",
volume = "17",
pages = "163--170",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy

AU - Ripley, R. Taylor

AU - Davis, Jeremy L.

AU - Klapper, Jacob A.

AU - Mathur, Aarti

AU - Kammula, Udai

AU - Royal, Richard E.

AU - Yang, James C.

AU - Sherry, Richard M.

AU - Hughes, Marybeth S.

AU - Libutti, Steven K.

AU - White, Donald E.

AU - Steinberg, Seth M.

AU - Dudley, Mark E.

AU - Rosenberg, Steven A.

AU - Avital, Itzhak

PY - 2010/1

Y1 - 2010/1

N2 - Background: Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. Methods: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. Results: A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. Conclusions: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.

AB - Background: Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy. Methods: Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008. Results: A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42-197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months. Conclusions: Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.

UR - http://www.scopus.com/inward/record.url?scp=74649086744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74649086744&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0677-0

DO - 10.1245/s10434-009-0677-0

M3 - Article

C2 - 19777192

AN - SCOPUS:74649086744

VL - 17

SP - 163

EP - 170

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -